key: cord-0793756-9d2309no
authors: Kubota, Takafumi; Kuroda, Naoto
title: Exacerbation of preexisting neurological symptoms and COVID-19 severity in patients with comorbid neurological disorders and COVID-19: A systematic review
date: 2020-11-01
journal: Clin Neurol Neurosurg
DOI: 10.1016/j.clineuro.2020.106349
sha: 6dbadb6e2f72bd6cf955e3bf1a5d34e4aef0f95c
doc_id: 793756
cord_uid: 9d2309no

BACKGROUND: Patients with chronic diseases usually develop severe 2019 coronavirus disease (COVID-19). However, little is known about the effects of COVID-19 on patients with neurological disorders. We conducted a systematic review to evaluate the severity of COVID-19 and its effect on preexisting neurological symptoms in patients with comorbid neurological disorder and COVID-19. METHODS: We searched the MEDLINE (PubMed) and medRxiv databases for reports of patients with both neurological disorders and COVID-19. Studies reporting data on changes in the symptoms of preexisting neurological disorders and/or the severity of COVID-19 were included. RESULTS: Twenty-six articles with 2278 patients with comorbid neurological disorder and COVID-19 were identified. Of 232 patients, 74 (31.9 %) showed exacerbation of preexisting neurological symptoms of dementia (55/92; 59.5 %), Parkinson’s disease (10/17; 58.8 %), epilepsy (1/1; 100 %), and unspecified neurological disorders (8/106; 7.5 %). Of 2168 patients, 478 (22.0 %) showed severe COVID-19 course. These included patients with cerebrovascular disease (86/445; 19.3 %), dementia (70/316; 22.2 %), Parkinson’s disease (25/214; 11.7 %), multiple sclerosis (28/71; 39.4 %), spinal cord injury (5/7; 71.4 %), and unspecified neurological disorders (254/1011; 25 %). CONCLUSIONS: Patients with comorbid neurological disorders and COVID-19 may develop more severe preexisting neurological symptoms and COVID-19. Clinicians should be aware of the risk of symptom exacerbation and severe COVID-19 in patients with neurological disease and should focus on the prevention and early care of COVID-19.

Coronavirus disease was first reported in China in December 2019 and has rapidly spread around the world. COVID-19 is one of the leading causes of critical pneumonia and death worldwide. Typically, 14-15% of patients with COVID-19 develop severe pneumonia and 1.5-2.3% die [1, 2] . Risk factors for severe COVID-19 include cardiovascular disease, diabetes mellitus, hypertension, and old age [3] .

A few cohort studies have shown that patients with preexisting neurological disorders who contracted COVID-19 developed more severe clinical symptoms and worse outcomes, compared to the general population [4, 5] . In addition, patients with neurological disorders such as Parkinson's disease and dementia who developed COVID-19 had a worsening of preexisting neurological symptoms [6, 7] .

However, the overall clinical and neurological outcomes of patients with comorbid neurological disorders and COVID-19 are unknown due to limited reports (few case reports or small cohort studies). Therefore, we conducted a systematic review to evaluate the exacerbation of preexisting neurological symptoms and the severity of COVID-19 in patients with comorbid neurological disorders and COVID-19.

A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [8] . This review protocol was not formally registered. The MEDLINE (accessed from PubMed) and medRxiv databases were searched systematically on May 22, 2020. In PubMed, the following key words (in the title/abstract) were used: ("COVID-19" OR "Coronavirus" OR "SARS-CoV-2" OR "2019-nCoV") AND ( "Neurology" OR "Neurologic" OR "Neurological" OR "Neuropathy" OR "Brain" OR "Spine" OR "Stroke" OR "Nerve" OR "Epilepsy" OR "Parkinson's disease" OR "Dementia" OR "Brain tumor" OR "Multiple Sclerosis" OR "Movement disorder" OR "Headache" OR "Tremor" OR "Amyotrophic lateral sclerosis" OR "Dystonia")". In medRxiv, the number of search terms that can be used is limited; therefore, the following key words were used: ("COVID 19" OR "SARS CoV 2") AND ("Neurologic" OR "Stroke" OR "Epilepsy" OR "Parkinson" OR "Dementia" OR "Multiple sclerosis"). The aforementioned neurological diseases were selected from among the chronic neurological diseases with a high prevalence [9, 10] .

We included studies based on the following criteria: (1) those reporting patients who had comorbid neurological disorders and COVID-19; (2) those that documented the severity of COVID-19 and/or changes in preexisting neurological symptoms; and (3) original reports such as case reports, letters, case series, or cohort studies. Case reports were included because so few large population-based studies of patients with comorbid neurological disorders and COVID-19 are available. We defined a severe case as a patient with severe/critical pneumonia or who had been admitted to the intensive care unit. We defined exacerbation as exacerbation of preexisting neurological disease-related symptoms. We excluded studies written in languages other than English.

We also excluded studies that only included patients who were critically ill or deceased.

Two reviewers (TK and NK) independently screened the titles and abstracts. After screening, a reviewer (TK) assessed the full texts of the selected articles and included those that met the inclusion criteria. Any disagreements were resolved by discussions between the reviewers (TK and NK).

A total of 1,702 studies were retrieved (866 papers from MEDLINE and 836 papers from medRxiv) on May 22, 2020. After title and abstract screening and duplicate removal, 313 studies were identified. The full-text screening of these studies led to the exclusion of 286 that did not meet the inclusion criteria. The remaining 26 studies were identified as eligible to be reviewed [6, 7, . Figure 1 outlines the selection process. Table 1 lists the characteristics of the included articles. A total of 2278 patients with comorbid neurological disorder and COVID-19 were included. The neurological disorders included cerebrovascular disease, Parkinson's disease, multiple sclerosis and related disorders, aquaporin-4 (AQP-4)-positive neuromyelitis optica spectrum disorder (NMOSD), dementia and cognitive disorder, epilepsy, spinal cord injury, systemic atrophy, myelopathy, intracranial mass, and unspecified neurological disorders. Since the selected articles did not always report both the exacerbation of neurological symptoms and severity of COVID-19, the patients were divided into two groups: 232 patients with comorbid neurological disorders and COVID-19 for whom the exacerbation of neurological symptoms was reported, and 2168 patients with comorbid neurological disorder and COVID-19 for whom the severe COVID-19 course was reported. Of the 232 patients in the first group, 74 (31.9%) showed an exacerbation of preexisting J o u r n a l P r e -p r o o f neurological symptoms, including patients with dementia (55/92; 59.5%), Parkinson's disease (10/17; 58 .8%), epilepsy (1/1; 100%), and unspecified neurological disorders (8/106; 7.5%), as shown in Table 2 Table 3 .

In this systematic review, our findings suggest that COVID-19 increases the risk of a worsening of preexisting neurological symptoms in patients with neurological disorders. In addition, our results indicate that patients with comorbid neurological disorders and COVID-19 may likely develop severe COVID-19. To our knowledge, this is the first systematic review to demonstrate the exacerbation of preexisting neurological symptoms and the severity of COVID-19 in patients with comorbid COVID-19 and neurological disorders.

We found that 32.3% of patients with comorbid neurological disorders and COVID-19 experienced a worsening of preexisting neurological symptoms. In particular, approximately 60% of patients with Parkinson's disease or dementia had an exacerbation of preexisting neurological symptoms. In general, the most common cause of symptom exacerbation in patients with Parkinson's disease was infection (25.6%), followed by anxiety (18.6%), medication errors (13.9%), and poor adherence to the treatment regimen (13.9%) [35] . Moreover, symptoms of COVID-19 and changes in the environment, such as hospitalization, may interrupt the scheduled intake of medication, resulting in the deterioration of symptoms. In addition, an infection induces the production of systemic and central nervous system cytokines and prostaglandins that cause acute cognitive declines and delirium in patients with dementia [36] . The presence of cytokines and monokines in the brain has been reported in patients with severe acute respiratory syndrome coronavirus [37] . Consequently, COVID-19 may trigger a cognitive decline or delirium in patients with dementia. Although the number of patients with epilepsy is small, they exhibited an exacerbation in symptoms. The association between seizures and COVID-19 has not been clearly determined; however, infection a common precipitating factor for the development of seizures in patients with epilepsy [38] [39] [40] . Thus, COVID-19 may worsen seizure control in patients with epilepsy. In contrast, patients with multiple sclerosis and related J o u r n a l P r e -p r o o f diseases did not exhibit neurological symptom exacerbations in our study. In contrast, a previous cohort study reported that viral infections were associated with temporal exacerbations in the symptoms of approximately 9% of patients with multiple sclerosis [41] . Our systematic review may not have detected symptom exacerbations in such patients due to the small sample size.

We found that 21.9% of patients with comorbid neurological disorders and COVID-19 developed severe COVID-19. The frequency of severe COVID-19 among these patients was greater than that of patients in general population studies (21.9% vs 14.2-15.7%) [1, 2] . Among patients with cerebrovascular disease or dementia, who comprised the majority of patients, 18.8% and 22.2%, respectively, experienced an increase in COVID-19 severity. This may be because such patients have risk factors for severe COVID-19, including old age, diabetes mellitus, and hypertension [3] . In patients with multiple sclerosis, the percentage of patients in whom COVID-19 severity increased was as high as 39.4%. Comorbidities, obesity, age, and progressive forms of multiple sclerosis have been reported as risk factors for severe COVID-19 in patients with comorbid multiple sclerosis [42] . Although the patients with multiple sclerosis in our study were relatively young (23-59 years), they may have had other comorbidities and progressive forms of the disorder. The severity of COVID-19 also increased in 71.4% of patients with spinal cord injury, although this population was small. Difficulty with spontaneous breathing and clearing respiratory secretions may worsen pneumonia in patients with spinal cord injury. In contrast, the frequency of patients with Parkinson's disease who experienced increased COVID-19 severity was low, compared to the general population (11.7% vs 14.2-15.7%) [1, 2] . This low percentage was inconsistent with the frequencies in patients with other predominantly elderly neurological diseases, such as dementia and stroke. In patients with epilepsy, the percentage of patients with severe COVID-19 was low (10.2%). Although the mean age of these patients is unknown, the studies may have included pediatric patients with epilepsy.

Our study had several limitations. First, most of the included studies were case reports or small cohort studies. Consequently, there may be large differences in the clinical settings between these reports. Second, the studies included in the systematic review may have been subject to selection and presentation bias. Severe or complicated cases may have been more likely to be published. However, worsening preexisting neurological symptoms might have been missed. Third, patients with unspecified neurological disorders were reported. Fourth, J o u r n a l P r e -p r o o f the criterion of severity varied slightly across studies. Therefore, the criteria in our study may not have been completely accurate and uniform.

In conclusion, our results suggest that patients with comorbid neurological disorders and COVID-19 may experience a worsening of preexisting neurological symptoms and are more likely to develop severe COVID-19 than the general population. Clinicians should be aware of the risks of an exacerbation of neurological symptoms and an increase in COVID-19 severity in patients with neurological diseases, and should focus on the prevention and early care of COVID-19. Further detailed retrospective and prospective large-cohort studies are needed to confirm the risk of an exacerbation of preexisting neurological symptoms and the clinical outcomes in patients with comorbid COVID-19 and neurological disorders. No English (9) Not available full text articles (8) Full 

Clinical characteristics of coronavirus disease 2019 in China

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan

Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in

Outcome of Parkinson's Disease Patients Affected by COVID-19

Clinical Presentation of COVID19 in Dementia Patients

The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration

The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK

Global, regional, and J o u r n a l P r e -p r o o f national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy

Characteristics of ischaemic stroke associated with COVID-19

Patients With Diabetes and Covid-19 in Wuhan

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Intravenous Thrombolysis for Stroke in a COVID-19 Positive Filipino Patient, a Case Report

Focal status epilepticus as unique clinical feature of COVID-19: A case report

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab

Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?

COVID-19 in persons with multiple sclerosis treated with ocrelizumab -a pharmacovigilance case series

Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury

Clinical Characteristics and Risk Factors for Developed COVID-19 Patients Transferring to Designated Hospital

Jianghan Fangcang Shelter Hospital: A Retrospective, Observational Study, SSRN Electron

Characterization and Clinical Course of 1000 Patients with COVID-19 in New York : retrospective case series student medical student assistant professor of medicine 3 Hamilton Southworth professor of epidemiology and medicine 4 assistant assistant professo

Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: a retrospective study

Effect of underlying comorbidities on the infection and severity of COVID-19 in South Korea

Development and validation of the COVID-19 severity index (CSI): a prognostic tool for early respiratory decompensation

Etiologic Subtypes of Ischemic Stroke in SARS-COV-2 Virus patients in a cohort of New York City hospitals

Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder

Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement

Stroke in patients with SARS-CoV-2 infection: case series

Rapid worsening in Parkinson's disease may hide COVID-19 infection

Clinical characteristics of exacerbations in parkinson disease

Systemic inflammation and delirium: Important co-factors in the progression of dementia

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study

Distribution of Seizure Precipitants Among Epilepsy Syndromes

The frequency and precipitating factors for breakthrough seizures among patients with epilepsy in Uganda

Clinical Viral Infections and Multiple Sclerosis

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis